Ulinastatin, A Multivalent Serine Protease Inhibitor, Improves Recovery of Pancreatic Cancer Patients Undergoing Laparoscopic Surgery

IF 0.4 4区医学 Q4 NUTRITION & DIETETICS

Current Topics in Nutraceutical Research Pub Date : 2023-07-07 DOI:10.37290/ctnr2641-452x.21:228-234

Xingjie Guo, Zhen Zhang, Huairui Li, A. Ho

引用次数: 0

Abstract

We aimed to explore the effect of an intravenous infusion of lidocaine combined with ulinastatin on perioperative analgesia and recovery for pancreatic cancer patients undergoing laparoscopic surgery. Postoperative extubation time, time of stay in the recovery room after anesthesia, gastrointestinal function recovery time, and hospital stay in the observation group were all lower in the group receiving ulinastatin. Also, there was a decrease in the Visual Analogue Scale scores for pain at rest and cough in the group receiving ulinastatin. The serum levels of pro-inflammatory cytokines interleukin-6, interleukin-8, and tumor necrosis factor-α were lower in the group receiving ulinastatin. In summary, ulinastatin improves the effect of lidocaine on perioperative analgesia and postoperative recovery of pancreatic cancer without additional side effects during laparoscopic-assisted surgery.

查看原文本刊更多论文

乌司他丁，一种多价丝氨酸蛋白酶抑制剂，改善癌症腹腔镜手术患者的恢复

目的探讨静脉输注利多卡因联合乌司他丁对癌症腹腔镜手术围手术期镇痛和恢复的影响。观察组术后拔管时间、麻醉后在恢复室停留时间、胃肠功能恢复时间、住院时间均低于乌司他丁组。此外，在接受乌司他丁治疗的组中，休息时疼痛和咳嗽的视觉模拟量表评分也有所下降。乌司他丁组血清促炎细胞因子白介素-6、白介素-8和肿瘤坏死因子-α水平较低。总之，在腹腔镜辅助手术中，乌司他丁改善了利多卡因对癌症围术期镇痛和术后恢复的影响，而没有额外的副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Topics in Nutraceutical Research 医学-药学

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Current Topics in Nutraceutical Research is an international, interdisciplinary broad-based peer reviewed scientific journal for critical evaluation of research on chemistry, biology and therapeutic applications of nutraceuticals and functional foods. The major goal of this journal is to provide peer reviewed unbiased scientific data to the decision makers in the nutraceutical and food industry to help make informed choices about development of new products. To this end, the journal will publish two types of review articles. First, a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, a critical evaluation of current human experimental data to help market and deliver the product for medically proven use. This journal will also serve as a forum for nutritionists, internists, neurologists, psychiatrists, and all those interested in preventive medicine. The common denominator of all of the topic to be covered by the journal must include nutraceuticals and/functional food. The following is an example of some specific areas that may be of interest to the journal. i) Role of vitamins, minerals, antioxidants and phytonutrients on cardiovascular health, cancer, diabetes, ocular health, mental health, men’s health, women’s health, infant nutrition, ii) Role of herbals on human health, iii) Dietary supplements and sleep, iv) Components of diet that may have beneficial effect on human health, v) regulation of apoptosis and cell viability, vi) Isolation and characterization of bioactive components from functional foods, vii) Nutritional genomics, and viii) Nutritional proteomics.